Skip to content

Study · Animal study (in vivo) · 2016

3 results

Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices.

Gupta V, Hwang BH, Doshi N, Banerjee A, Anselmo AC, Mitragotri S

Annals of biomedical engineering10 Feb 2016Cited by 41 (Europe PMC)

PMID26864536 (opens in a new tab)DOI10.1007/s10439-016-1558-x (opens in a new tab)PepBankPUB-26864536
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In vivo, mucoadhesive exenatide devices increased relative bioavailability 80-fold compared with intestinal injections.

    In plain wordsIn animals, exenatide devices increased relative bioavailability compared with intestinal injections.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseRelative bioavailability
    Study

    n: not reported in source

    Comparator
    Intestinal injections
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study.

    Measurements

    Relative bioavailability enhancement
    80 fold
    exenatide devices versus intestinal injections

    Source sentences

    Summary
    In-vivo administration of the devices provided significant enhancement of drug absorption with 13- and 80-fold enhancement of relative bioavailability for insulin and exenatide compared to intestinal injections
    1 context sentence
    Summary · context
    Devices were prepared with a blend of FDA-approved polymers, carbopol, pectin and sodium carboxymethylcellulose, and were tested for drug carrying capability, in vitro release, Caco-2 permeability, and in vivo efficacy for insulin and exenatide.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In vivo, mucoadhesive exenatide devices increased half-life compared with intestinal injections.

    In plain wordsIn animals, exenatide devices increased half-life compared with intestinal injections.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHalf-life
    Study

    n: not reported in source

    Comparator
    Intestinal injections
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study.

    Source sentences

    Summary
    In-vivo administration of the devices provided significant enhancement of drug absorption with 13- and 80-fold enhancement of relative bioavailability for insulin and exenatide compared to intestinal injections with significant increase in half-lives, thus resulting in prolonged blood glucose reduction.
    1 context sentence
    Summary · context
    Devices were prepared with a blend of FDA-approved polymers, carbopol, pectin and sodium carboxymethylcellulose, and were tested for drug carrying capability, in vitro release, Caco-2 permeability, and in vivo efficacy for insulin and exenatide.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In vivo, mucoadhesive exenatide devices prolonged blood glucose reduction compared with intestinal injections.

    In plain wordsIn animals, exenatide devices prolonged glucose reduction compared with intestinal injections.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDuration of glucose reduction
    Study

    n: not reported in source

    Comparator
    Intestinal injections
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study.

    Source sentences

    Summary
    In-vivo administration of the devices provided significant enhancement of drug absorption with 13- and 80-fold enhancement of relative bioavailability for insulin and exenatide compared to intestinal injections with significant increase in half-lives, thus resulting in prolonged blood glucose reduction.
    1 context sentence
    Summary · context
    Devices were prepared with a blend of FDA-approved polymers, carbopol, pectin and sodium carboxymethylcellulose, and were tested for drug carrying capability, in vitro release, Caco-2 permeability, and in vivo efficacy for insulin and exenatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.